RecruitingNCT07382752
Decoupling Immunotherapy Toxicity and Cancer Response
Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity
Sponsor
M.D. Anderson Cancer Center
Enrollment
1,200 participants
Start Date
Jan 9, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Age ≥ 18 years
- Plan to start immune checkpoint inhibitor for cancer therapy
Exclusion Criteria2
- No baseline blood collection prior to initiation
- At time of evaluation not determined to be a good candidate for evaluation of outcome events by the principal investigator
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07382752
Related Trials
SBRT-LATTICE-PATHY
NCT076452611 location
A First-in-Human Study of the CIPHER System During Brain Surgery for Newly Diagnosed Glioma
NCT074657961 location
Strategy for EArly Recognition of Cancer, COPD & Heart Failure in the Emergency Department
NCT073912801 location
Improving the Heart Health of Home Health Aides
NCT070673982 locations
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NCT0749117218 locations